LeonaBio grants 300,000 stock options to counsel

LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock.

Rhea-AI Filing Summary

LeonaBio, Inc. reported that its General Counsel and Chief Compliance Officer, Mark Worthington, received a grant of stock options covering 300,000 shares of common stock. The options have an exercise price of $9.54 per share and expire on April 8, 2036.

The award was classified as a grant or other acquisition of a derivative security, with 300,000 options held directly after the transaction. According to the grant terms, the underlying shares are scheduled to vest monthly over 48 months, subject to his continued service as a provider under LeonaBio’s 2026 Equity Incentive Plan.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Worthington Mark

Role GENERAL COUNSEL and CCO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	300,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 300,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

Key Figures

Stock options granted: 300,000 options Exercise price: $9.54 per share Expiration date: April 8, 2036 +1 more

4 metrics

Stock options granted 300,000 options Grant of stock options to General Counsel and CCO

Exercise price $9.54 per share Exercise price of granted stock options

Expiration date April 8, 2036 Option expiration for 300,000 granted options

Vesting schedule 48 months monthly Options vest monthly over 48 months, subject to continued service

Key Terms

Stock Option (Right to Buy), derivative security, 2026 Equity Incentive Plan, Service Provider

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

derivative security financial

"The award was classified as a grant or other acquisition of a derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

2026 Equity Incentive Plan financial

"as defined in the Issuer's 2026 Equity Incentive Plan"

Service Provider financial

"subject to the optionee continuing to be a Service Provider"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LeonaBio (LONA) report for Mark Worthington?

LeonaBio reported that General Counsel and Chief Compliance Officer Mark Worthington received a grant of 300,000 stock options. These options give him the right to buy common shares at a fixed price and represent a compensation-related equity award rather than an open-market stock purchase or sale.

How many LeonaBio (LONA) stock options were granted in this Form 4?

The filing shows a grant of 300,000 stock options to Mark Worthington. Each option corresponds to one share of LeonaBio common stock, giving rights over 300,000 underlying shares if exercised according to the plan’s vesting and exercise terms in the future.

What is the exercise price and expiration date of the LeonaBio (LONA) options?

The stock options have an exercise price of $9.54 per share and expire on April 8, 2036. This means Worthington can choose to buy shares at $9.54, if vested, any time before the 2036 expiration date, subject to the plan’s conditions.

How do the LeonaBio (LONA) options granted to Mark Worthington vest?

The 300,000 stock options vest in monthly installments over 48 months from the grant date. Vesting requires Worthington to continue as a “Service Provider” under LeonaBio’s 2026 Equity Incentive Plan through each monthly vesting date for the relevant portion to become exercisable.

Is this LeonaBio (LONA) Form 4 a market buy or sell of common shares?

The Form 4 reflects a grant of stock options, not a market purchase or sale of common shares. It is a compensation-related award classified as a derivative security acquisition, with no reported open-market buying or selling of LeonaBio’s common stock in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Worthington Mark

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL and CCO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.54	04/09/2026		A		300,000		(1)	04/08/2036	Common Stock	300,000	$0	300,000	D

Explanation of Responses:

1. The shares subject to the option shall be scheduled to vest monthly over a term of 48 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates.

	/s/ Mark Worthington	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)